Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study
Y Edahiro, K Ohishi, A Gotoh, K Takenaka… - International journal of …, 2022 - Springer
Ropeginterferon alfa-2b is a novel, site-selective, monopegylated recombinant human
interferon alfa-2b. Safety and efficacy of ropeginterferon alfa-2b for the treatment of …
interferon alfa-2b. Safety and efficacy of ropeginterferon alfa-2b for the treatment of …
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
P Guglielmelli, B Mora, F Gesullo… - American Journal of …, 2024 - Wiley Online Library
The variant allele frequency (VAF) of driver mutations (JAK2, CALR) in myeloproliferative
neoplasms is associated with features of advanced disease and complications. Ruxolitinib …
neoplasms is associated with features of advanced disease and complications. Ruxolitinib …
[HTML][HTML] Hemorrhage in essential thrombocythemia or polycythemia vera: epidemiology, location, risk factors, and lessons learned from the literature
C Nicol, K Lacut, B Pan-Petesch… - Thrombosis and …, 2021 - thieme-connect.com
Hemorrhage is a well-known complication of essential thrombocythemia (ET) and
polycythemia vera (PV), but evidence-based data on its management and prevention are …
polycythemia vera (PV), but evidence-based data on its management and prevention are …
[HTML][HTML] Mutant calreticulin in the myeloproliferative neoplasms
D Prins, CG Arias, T Klampfl, J Grinfeld, AR Green - Hemasphere, 2020 - journals.lww.com
Mutations in the gene for calreticulin (CALR) were identified in the myeloproliferative
neoplasms (MPNs) essential thrombocythaemia (ET) and primary myelofibrosis (MF) in …
neoplasms (MPNs) essential thrombocythaemia (ET) and primary myelofibrosis (MF) in …
[HTML][HTML] The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
M Tiribelli, F Palandri, E Sant'Antonio… - Bone Marrow …, 2020 - nature.com
Allogeneic hematopoietic stem-cell transplantation (HSCT) is, at present, the only potentially
curative therapy for myelofibrosis (MF). Despite many improvements, outcomes of HSCT are …
curative therapy for myelofibrosis (MF). Despite many improvements, outcomes of HSCT are …
Heterogeneity in myeloproliferative neoplasms: Causes and consequences
J O'Sullivan, AJ Mead - Advances in biological regulation, 2019 - Elsevier
Myeloproliferative neoplasms (MPNs) are haematopoietic stem cell-derived clonal disorders
characterised by proliferation of some or all myeloid lineages, depending on the subtype …
characterised by proliferation of some or all myeloid lineages, depending on the subtype …
The role of JAK2 inhibitors in MPNs 7 years after approval
F Passamonti, M Maffioli - Blood, The Journal of the American …, 2018 - ashpublications.org
Myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia
vera (PV), and primary myelofibrosis (MF). Phenotype-driver mutations of JAK2, CALR, and …
vera (PV), and primary myelofibrosis (MF). Phenotype-driver mutations of JAK2, CALR, and …
[HTML][HTML] NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells
BA Fenerich, JC Fernandes… - Signal transduction and …, 2020 - nature.com
Recent data indicate that IGF1R/IRS signaling is a potential therapeutic target in BCR-ABL1-
negative myeloproliferative neoplasms (MPN); in this pathway, IRS2 is involved in the …
negative myeloproliferative neoplasms (MPN); in this pathway, IRS2 is involved in the …
[HTML][HTML] Ruxolitinib-associated infections in polycythemia vera: review of the literature, clinical significance, and recommendations
P Sadjadian, K Wille, M Griesshammer - Cancers, 2020 - mdpi.com
Simple Summary Polycythemia vera (PV) is a chronic blood disease characterized by
elevated red blood cells and splenomegaly. About 98% of all PV patients harbor the JAK2 …
elevated red blood cells and splenomegaly. About 98% of all PV patients harbor the JAK2 …
Myeloproliferative neoplasms in children, adolescents, and young adults
N Kucine - Current hematologic malignancy reports, 2020 - Springer
Abstract Purpose of Review Myeloproliferative neoplasms are traditionally seen in older
adults, making them poorly understood in younger patients. Clinical presentation, genetic …
adults, making them poorly understood in younger patients. Clinical presentation, genetic …